HONG KONG – A Chinese maker of novel oncology, cardiovascular and metabolic drugs is floating shares in Hong Kong next month and has developed a plan to set itself apart from the pack. Read More

TOKYO – Japan's Taiho Oncology Inc. reported positive results from a global phase III trial of its oral combination anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC). Read More

HONG KONG – A Japanese technology company has reached an agreement with a UK-based orphan drug developer to co-develop and sell an orphan drug in Japan. Read More

HONG KONG – Researchers from the Riken Center for Life Science Technologies in Japan said they have gained new insights into the role of a chemokine protein in the enhancement of stem cell pluripotency, an improved understanding that could lead to the development of more stable and clinically useful stem cells. Read More

SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang and Shanghai, won FDA approval for its third cancer drug, oxaliplatin, an alkylating agent used to treat colorectal cancer, as the firm's pioneering efforts as a Chinese pharma to pass the hurdles of developed markets begin to pay off. Read More

China Biologic Products Inc., of Beijing, said it priced a follow-on offering of about 1.6 million shares of common stock at a price of $38 per share. Of those, the company will be offering 800,000 shares for gross proceeds of about $30.4 million. The remaining 750,000 shares will be sold by a company stockholder, and China Biologic will not receive any of those proceeds. Read More

Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., of Tokyo, appointed Marty Golden vice president, government affairs. Read More